Bayer

Andrea Germanos, staff writer
bottles of Roundup
The chemical company is asking a federal appeals court to reverse its ruling in...
Julia Conley, staff writer
New documents reveal Monsanto's 'fusion center' aimed at targeting and...

Further

Up there in the annals of multinational corporations doing heinous things in the name of obscene profits comes the German-based Bayer's response to India ending the pharma giant's monopoly for a pricey new anti-cancer drug, thus allowing a small Indian company to make a generic version that poor sick people can afford. A year of Bayer's Nexavar costs $96,000 in the U.S. and $69,000 in India, 41 times the per capita income; India's Natco Ltd. made it for $177 a year. Outraged Bayer officials...